CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows from Operating Activities:
Net (loss) income	$ (29,956)	$ 86,153
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)	17,956	19,705
Non-cash compensation	19,624	15,990
Amortization and impairment of operating lease right of use assets	25,427	34,782
Loss on disposal of property and equipment	346	507
Loss on personal care divestiture	2,186	0
Merger termination fee	106,000	0
Deferred income taxes	15,417	19,031
Equity in (earnings) loss from equity method investments	(9,366)	442
Amortization of deferred debt issuance costs	743	743
Return on equity method investments	4,309	3,798
Investment impairment	0	3,009
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(32,934)	(18,266)
Other current assets	(15,434)	(19,929)
Operating lease right of use assets	(2,803)	(2,323)
Other assets	273	283
Accounts payable	(8,839)	5,886
Accrued expenses	10,340	(26,790)
Other long-term obligations	(3,156)	243
Operating lease liabilities	(23,256)	(30,864)
Net cash provided by operating activities	76,877	92,400
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	25	89
Proceeds from the sale of property and equipment	100	66
Purchases of property and equipment	(3,728)	(4,338)
Investments in technology assets	(6,881)	(848)
Investment in equity method investee	0	(637)
Purchase of cost method investment	0	(15,000)
Return of investment	150	0
Proceeds from personal care divestiture	47,787	0
Acquisitions of businesses, net of cash acquired	(350)	(71,952)
Net cash provided by (used in) investing activities	37,103	(92,620)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	100	1,078
Proceeds from issuance of stock under employee stock purchase plan	2,602	2,857
Shares withheld to pay taxes on non-cash compensation	(4,413)	(7,949)
Noncontrolling interest contributions	1,232	2,100
Noncontrolling interest distributions	(1,614)	(1,425)
Proceeds from sale of noncontrolling interest	0	3,941
Proceeds from borrowings under revolving line of credit	23,000	484,000
Repayments of borrowings under revolving line of credit	(23,000)	(465,500)
Principal payments of long-term obligations	(67,113)	(10,126)
Purchase of company stock	0	(17,351)
Payment of accrued contingent consideration	(4,091)	(5,714)
Purchase of noncontrolling interest	(800)	0
Net cash used in financing activities	(74,097)	(14,089)
Net increase (decrease) in cash, cash equivalents and restricted cash	39,883	(14,309)
Cash, cash equivalents and restricted cash at beginning of period	54,133	45,769
Cash, cash equivalents and restricted cash at end of period	94,016	31,460
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	19,787	9,153
Cash Paid For Infinity ZPIC Interest	0	11,544
Cash paid for income taxes, net of refunds received	24,318	23,582
Cash paid for operating lease liabilities	26,059	33,187
Cash paid for finance lease liabilities	8,462	1,074
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	25,261	36,980
Right of use assets obtained in exchange for finance lease liabilities	34,964	1,846
Reductions to right of use assets resulting from reductions to operating lease liabilities	15,135	3,387
Reductions to right of use assets resulting from reductions to finance lease liabilities	1,209	564
Accrued contingent consideration	0	19,195
Noncontrolling interest contribution	$ 0	$ 8,900